Hazlett Burt & Watson Inc. Boosts Stake in Becton, Dickinson and Company (NYSE:BDX)

Hazlett Burt & Watson Inc. grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 217.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 888 shares of the medical instruments supplier’s stock after buying an additional 608 shares during the period. Hazlett Burt & Watson Inc.’s holdings in Becton, Dickinson and Company were worth $214,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. WR Wealth Planners LLC increased its stake in shares of Becton, Dickinson and Company by 1.4% in the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares during the period. Clear Creek Financial Management LLC increased its stake in shares of Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC increased its stake in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the period. Central Pacific Bank Trust Division increased its stake in shares of Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC grew its position in Becton, Dickinson and Company by 3.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 48 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.4 %

BDX opened at $234.33 on Tuesday. The firm has a 50 day moving average price of $237.52 and a 200 day moving average price of $235.10. The company has a market cap of $67.73 billion, a PE ratio of 48.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.43. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $259.92. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Analyst Ratings Changes

Several research firms recently commented on BDX. Raymond James dropped their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI lifted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.